CorMedix (CRMD) Misses Q4 EPS by 1c

CorMedix (NASDAQ: CRMD) reported Q4 EPS of ($0.20), $0.01 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $30 thousand versus the consensus estimate of $3.5 thousand.

For earnings history and earnings-related data on CorMedix (CRMD) click here.

You May Also Be Interested In

• Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
• Analog Devices climbs as fiscal Q3 results, Q4 outlook beat forecasts
• Jaguar Health (JAGX) Tops Q2 EPS by 3647c